ENCell, a company specializing in cell and gene therapy (CGT), announced on the 24th that it has signed a strategic partnership agreement with Cell Resources Corporation (CRC), a regenerative medicine subsidiary of Japan's Alfresa Group.
Since signing an MOU in March to strengthen cooperation in the CGT field, YENCELL and CRC have been discussing specific business collaboration plans. This agreement concretizes the MOU's contents into practical business implementation, marking the full launch of the two companies' cooperation in the field of regenerative medicine.
Through this collaboration, CRC will introduce ENCell's next-generation mesenchymal stem cell (MSC) treatment, EN001, to Japanese pharmaceutical companies and biotech companies, creating licensing (L/O) and local partnership opportunities. The two companies also agreed to share information on potential customers requiring CDMO (Contract Development and Manufacturing Organization) services and expand business opportunities in both Korea and Japan.
ENCell will provide CRC with comprehensive advisory services, including analysis of the Japanese regenerative medicine market, business strategy development, facility operation, and manufacturing capability verification. Furthermore, it plans to transfer its CAR-T and MSC technology expertise to support CRC's business competitiveness. CRC will be responsible for establishing a regenerative medicine supply chain within the Alfresa Group and will collaborate on the global licensing of EN001 and the expansion of its CDMO business in Japan.
Currently, Encell is developing EN001 for indications including Charcot-Marie-Tooth disease (CMT), Duchenne muscular dystrophy (DMD), and sarcopenia, and is pursuing a global licensing strategy. This partnership is expected to serve as a crucial foundation for expanding global technology transfer and partnerships, along with entry into the Japanese market.
Jang Jong-wook, CEO of Encell, said, “Through this partnership, we will accelerate the development of new drug pipelines and technology transfers in Japan, and also generate results in the CDMO business.”
- See more related articles
You must be logged in to post a comment.